Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the condition. Researchers at Rush University Medical Center and scientists from several National Institutes of Health-funded institutions, in collaboration with international peers, described the newly-named pathway to dementia, Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, in a report published in the journal Brain.

"We proposed a new name to increase recognition and research for this common cause of dementia, the symptoms of which mimic Alzheimer's dementia but is not caused by plaques and tangles (the buildup of beta amyloid proteins that Alzheimer's produces). Rather, LATE dementia is caused by deposits of a protein called TDP-43 in the brain," said Dr. Julie Schneider, senior author of the Brain paper and associate director of the Rush Alzheimer's Disease Center.

Alzheimer's, the most common form of dementia, causes loss of cognitive functions --especially memory, but also --results in changes in everyday functional abilities and behavior. In the past, most cases of dementia with memory loss were assumed to be Alzheimer's disease.

Now there is growing appreciation that a variety of diseases and disease processes contribute to dementia with memory loss. Each of these diseases appears differently in brain samples examined at autopsy of people who died with these conditions.

'Oldest old' are at greatest risk of LATE

It has become increasingly clear that in advanced age, a large number of people had symptoms of dementia without the telltale signs of Alzheimer's disease in their brains at autopsy. Emerging research seems to indicate that TDP-43, while not a stand-alone explanation, is a large contributor to that phenomenon.

The function of normal TDP-43 (transactive response DNA binding protein of 43 kDa) is related to how cells use DNA to make proteins. In disease, TDP protein becomes misfolded (abnormally structured) and moves from its normal location in the cell. Abnormal TDP-43 was first recognized in amyotrophic lateral sclerosis and frontotemporal lobar degeneration, relatively uncommon diseases.

Recent research shows that misfolded TDP-43 protein is very common in older adults. Roughly 25 percent of individuals more than 85 years of age have enough misfolded TDP-43 protein to affect their memory and/or thinking abilities.

The authors wrote that LATE is an under-recognized condition with a very large impact on public health. They emphasized that the "oldest-old" are at greatest risk, and they believe that the public health impact of LATE is at least as large as Alzheimer's in this group.

The clinical and neurocognitive features of LATE affect multiple areas of cognition, ultimately impairing activities of daily life. Based on existing research, the authors suggested that LATE progresses more gradually than Alzheimer's. However, LATE combined with Alzheimer's - which is common for these two highly prevalent brain diseases - appears to cause a more rapid decline than either would alone.

Researchers call for removing people with LATE from studies of Alzheimer's drugs

A key recommendation was for routine autopsy evaluation and classification of LATE. The researchers suggest the autopsy diagnosis be in three stages, according to where in the brain TDP-43 is detected:
  • Stage 1: amygdala only
  • Stage 2: amygdala and hippocampus
  • Stage 3: amygdala, hippocampus and middle frontal gyrus

Additional recommendations include highlighting the great need for the development of biomarkers to increase recognition during life, further pathological studies, and the generation of new animal models for studying LATE. Suggestions were provided for possible strategies to help guide future therapeutic interventions, including the importance of removing subjects with LATE from clinical trials of Alzheimer's treatments, which could significantly improve the chances of successful Alzheimer's breakthroughs. The researchers also discussed the importance of more epidemiological, clinical, neuroimaging and genetic studies to better characterize LATE, and the need for research in diverse populations.

"As we continue to make large strides in our understanding of memory loss and dementia in aging, we have renewed confidence that we will be able to work towards a more individualized approach to preventions and treatments," said Schneider.

Peter T Nelson, Dennis W Dickson, John Q Trojanowski, Clifford R Jack, Patricia A Boyle, Konstantinos Arfanakis, Rosa Rademakers, Irina Alafuzoff, Johannes Attems, Carol Brayne, Ian T S Coyle-Gilchrist, Helena C Chui, David W Fardo, Margaret E Flanagan, Glenda Halliday, Suvi R K Hokkanen, Sally Hunter, Gregory A Jicha, Yuriko Katsumata, Claudia H Kawas, C Dirk Keene, Gabor G Kovacs, Walter A Kukull, Allan I Levey, Nazanin Makkinejad, Thomas J Montine, Shigeo Murayama, Melissa E Murray, Sukriti Nag, Robert A Rissman, William W Seeley, Reisa A Sperling, Charles L White III, Lei Yu, Julie A Schneider.
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.
Brain, 30 April 2019. doi: 10.1093/brain/awz099.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...